Brind.

FDA granted Fast Track designation to Amorfix for its antibody therapeutic targeting Alzheimer's Disease.

5 reports, 1 independent Updated Aug 13
Gone quiet
Reports
5
Developments
2
Repetition
60%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

FDA granted Fast Track designation to Amorfix for its antibody therapeutic targeting Alzheimer's Disease.

Who's involved

What this event is mainly about
FDAAmorfix (Canada)

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA grants Fast Track designation to Amorfix for its AD antibody therapeutic.1 source
  2. Amorfix announced development of antibodies for multiple neurodegenerative diseases and secured financing.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, enhancing program’s potential for
  • GlobeNewswireProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference Presentation to highlight the Compan
  • GlobeNewswireProMIS Neurosciences Announces Private Placement Financing $2.4 million private financing plus an additional $6.8 million of proceeds due to exercise of warrants and $0.8 million from a registered of
  • GlobeNewswireProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease FDA designation highlights the potential of PMN310 to deliver a more targeted approa
  • GlobeNewswireProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease FDA designation highlights the potential of PMN310 to deliver a more targeted approa